Autonomix Medical, Inc. Common Stock

AMIX

Autonomix Medical, Inc. (AMIX) is a medical device company that develops and markets innovative solutions aimed at improving minimally invasive surgical procedures. Focused on addressing unmet clinical needs, the company offers advanced surgical technologies designed to enhance precision, safety, and patient outcomes in various medical fields.

$0.45 -0.02 (-3.49%)
🚫 Autonomix Medical, Inc. Common Stock does not pay dividends

Company News

Autonomix Medical, Inc. Featured in Two Innovation in Interventional Cardiology Podium Presentations at the Transcatheter Cardiovascular Therapeutics® (TCT®) Annual Scientific Conference
GlobeNewswire Inc. • Autonomix Medical, Inc. • October 24, 2025

Autonomix Medical will present two podium sessions at the Transcatheter Cardiovascular Therapeutics Annual Scientific Conference, highlighting their first-in-human clinical study on transvascular energy delivery for pancreatic cancer pain mitigation.

Autonomix Medical, Inc. to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech
GlobeNewswire Inc. • Brad Hauser • August 15, 2025

Autonomix Medical, a medical device company developing innovative nerve-targeted treatment technologies, will present at the Webull Financial Corporate Connect Webinar Series on August 21, 2025, discussing their microchip-based intravascular nerve sensing platform.

Autonomix Medical, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc. • N/A • March 21, 2025

Autonomix Medical, Inc. (NASDAQ: AMIX) announced the grant of a stock option to a new non-executive employee as an inducement to their employment. The option has a 10-year term and vests over four years, subject to continued service.

Autonomix Medical, Inc. Announces U.S. Patent Granted Covering the Treatment of Cancerous Tumors and Cancer Related Pain with Company’s Proprietary Catheter-Based Technology
GlobeNewswire Inc. • N/A • December 30, 2024

Autonomix Medical, Inc. has been granted a U.S. patent for its technology that aims to treat cancerous tumors and cancer-related pain. The company's preclinical studies have shown promising results in reducing metastases and tumor mass, and it plans to further explore the potential of its technology to slow pancreatic cancer growth and metastasis.

A.M.AUTONOMY Showcases MAP-TORCH for 3D Construction Digitalization at KINTEX
GlobeNewswire Inc. • N/A • November 18, 2024

A.M.AUTONOMY will showcase its 'MAP-TORCH' solution, which digitizes construction sites into 3D, at the Smart Construction Expo in South Korea. The solution can also integrate sensors for detecting hazardous gases and radiation, aiding in accident prevention in nuclear facilities.

Related Companies